Abstract
Abstract not available.
Highlights
Lesion counts decreased over time in both Black and White participants
■ Rates of treatment-emergent adverse events (TEAEs) were similar for TAZ-treated Black and White participants; TEAEs were mostly mild or moderate and unrelated to treatment (Table 1)
In White participants, tazarotene was significant versus vehicle for all 3 efficacy assessments
Summary
■ In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321),[5,6] participants with moderate-to-severe acne were randomized 1:1 to tazarotene 0.045% lotion or vehicle lotion (N=1614). In these studies, CeraVe® hydrating cleanser and CeraVe® moisturizing lotion (L’Oreal, NY) were provided as needed for optimal moisturization/cleaning of the skin. ■ This pooled, post hoc analysis included subsets of participants segmented by White (n=1191) or Black race (n=262). ■ Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment success; treatment-emergent adverse events (TEAEs) and cutaneous safety and tolerability were evaluated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
